DEFM14A: TuHURA Biosciences to Acquire Kineta in Strategic Cash and Stock Merger, Expanding Immuno-Oncology Pipeline

TuHURA Biosciences, Inc. has entered into a definitive agreement to acquire Kineta, Inc. in a cash and stock transaction, aiming to integrate Kineta's novel VISTA blocking immunotherapy and other assets to enhance its immuno-oncology pipeline.

Summary

• TuHURA Biosciences, Inc. will acquire Kineta, Inc. through a series of mergers, with Kineta becoming a wholly-owned privately held subsidiary of TuHURA.
• Kineta stockholders will receive a combination of TuHURA Common Stock and cash, with the TuHURA share value fixed at $5.7528 for calculation purposes, though the market value will fluctuate.
• Kineta stockholders are expected to hold approximately 7% of the issued and outstanding shares of TuHURA immediately following the completion of the Mergers.
• Kineta has agreed to sell certain non-VISTA assets, including Partnered Programs (Merck, Genentech, FAIR) to HCRX Investments Holdco, L.P. for $1.00 cash plus milestone/royalty payments, and its KCP506 pain treatment candidate to Pacira Pharmaceuticals, Inc. for $450,000.
• The existing CD27 Option and License Agreement with GigaGen, Inc. has been terminated, with GigaGen waiving $180,000 in accrued fees and Kineta assigning all related rights back to GigaGen.
• The merger is contingent on TuHURA stockholders approving an increase in authorized shares from 75 million to 200 million, and Kineta stockholders approving the Merger Agreement.
• TuHURA is required to complete a Concurrent Investment of at least $20 million in gross proceeds as a condition for the merger to close.
• Kineta's estimated net working capital deficit at closing must not exceed $6 million, a reduction from the previously agreed $12 million.
• TuHURA has provided Kineta with advances and loans totaling $695,000 (as of Dec 31, 2024) and an additional $750,000 (subsequent to Dec 31, 2024) for clinical trial and working capital expenses, which will be credited against the cash component of the merger consideration.
• Kineta reported a net loss of $17.1 million for the year ended December 31, 2024, and had cash of $634,000 and an accumulated deficit of $182.9 million as of that date, raising substantial doubt about its ability to continue as a going concern without the merger.
• TuHURA reported a net loss of $22.6 million for the year ended December 31, 2024, and had cash of $12.7 million and an accumulated deficit of $111.1 million as of that date.

Sentiment

Score: 6

Explanation: The document outlines a strategic merger that, while necessary for Kineta due to severe financial distress and operational challenges, is presented as a positive step for both companies. For TuHURA, it's an expansion of its pipeline and capabilities. The tone is factual, but the underlying circumstances for Kineta are dire, making the merger a survival strategy. The overall sentiment is cautiously positive, as the merger aims to create a stronger combined entity, despite the significant risks and Kineta's prior struggles.

Positives

• The merger provides Kineta stockholders with an opportunity to realize value through a combination of cash and stock in TuHURA, avoiding potential liquidation.
• Kineta's asset sales (Partnered Programs, KCP506, CD27) provide immediate cash and potential future milestone/royalty payments to Kineta stockholders.
• The transaction is expected to create meaningful synergies by combining key assets, capabilities, and intellectual property, potentially accelerating product innovation for TuHURA.
• TuHURA's acquisition of Kineta's KVA12123 VISTA blocking immunotherapy provides a Phase 2 complementary technology to TuHURA's existing portfolio, expanding its product candidate pipeline.
• The fixed TuHURA Share Value in the merger consideration provides certainty regarding the number of shares Kineta stockholders will receive, regardless of market fluctuations.
• Both TuHURA and Kineta boards of directors unanimously approved the merger, indicating strong internal support for the transaction.

Negatives

• Kineta's severe financial distress, including recurring net losses, negative cash flows, and an accumulated deficit of $182.9 million, forced it to seek strategic alternatives, including potential liquidation if the merger fails.
• Kineta's workforce was significantly reduced by approximately 64% as part of a corporate restructuring to preserve cash.
• Kineta's VISTA-101 Phase 1/2 clinical trial enrollment was paused due to certain investors failing to fulfill contractual funding obligations.
• The market value of the merger consideration for Kineta stockholders will fluctuate with TuHURA Common Stock price, despite the fixed TuHURA Share Value, introducing market risk.
• Kineta stockholders will have a significantly lower ownership (approximately 7%) and voting interest in TuHURA post-merger, reducing their influence over management.
• TuHURA's lead product candidate, IFx-2.0, is subject to a partial clinical trial hold by the FDA due to CMC requirements, which could delay its Phase 3 trial initiation.
• The unaudited pro forma financial information is preliminary and actual financial positions and results may differ materially, with no guarantee of anticipated synergies or cost savings.

Risks

• The merger may not be completed, or the Merger Agreement may be terminated, leading to negative impacts on stock prices and future business results for both companies.
• The market value of the Merger Consideration that Kineta stockholders will receive is uncertain due to fluctuations in TuHURA Common Stock price and dependence on Kineta's net working capital.
• If the merger is not successfully completed, Kineta's Board of Directors may decide to pursue a dissolution and liquidation, potentially resulting in a total loss for Kineta stockholders.
• TuHURA requires substantial additional capital (at least $20 million gross proceeds from a Concurrent Investment) to finance its operations, and there is no guarantee it will obtain this financing on acceptable terms or at all.
• The announcement and pendency of the Merger Agreement could disrupt current plans and operations, affecting the ability to retain customers and key personnel.
• The merger involves substantial costs, including financial advisory, legal, and accounting fees, some of which are non-recurring and payable regardless of merger completion.
• Kineta's directors and executive officers have interests in the merger that are different from general stockholders, including severance benefits and accelerated equity awards.
• The Merger Agreement contains provisions that could discourage competing acquirers for Kineta, potentially limiting higher offers.
• Lawsuits challenging the mergers could delay or prevent completion and incur significant costs.
• TuHURA's bylaws designate Delaware courts as exclusive forums for certain disputes, potentially limiting stockholders' ability to choose a judicial forum.
• The Asset Sales by Kineta are subject to closing conditions and may not be consummated, which could adversely affect Kineta's business and financial condition if the merger still proceeds.
• TuHURA is a clinical-stage company with a limited operating history and no products approved for commercial sale, making future profitability uncertain.
• TuHURA has incurred significant losses since inception and expects to continue incurring losses, raising substantial doubt about its ability to continue as a going concern.
• TuHURA's clinical trials may experience substantial delays or fail to demonstrate adequate safety and efficacy, preventing or delaying regulatory approval.
• TuHURA relies on third parties for manufacturing and clinical trials, and their failure to perform could harm development and commercialization efforts.
• TuHURA's product candidates may cause undesirable side effects, halting development or limiting commercial potential.
• TuHURA's technology platforms are new and unproven, facing significant challenges in development and regulatory approval.
• TuHURA may face intense competition from larger, more established biopharmaceutical companies.
• TuHURA's ability to generate revenue depends on obtaining adequate coverage and reimbursement from third-party payors, which may be limited or unavailable.
• TuHURA is subject to stringent privacy and cybersecurity laws, and breaches could result in significant liability and reputational harm.
• TuHURA's intellectual property protection may be inadequate, or it may face infringement claims from third parties.
• Kineta has identified material weaknesses in its internal control over financial reporting, which could impact financial reporting accuracy and timeliness.

Future Outlook

Both TuHURA and Kineta are clinical-stage biotechnology companies with no current product sales. Their future profitability is highly dependent on the successful completion of clinical trials, obtaining regulatory approvals for their product candidates (IFx-2.0, KVA12123, IFx-3.0, and other pipeline assets), and successful commercialization. Both companies anticipate incurring significant expenses for research, development, and potential commercialization, requiring substantial additional funding. TuHURA expects its existing capital to fund operations into late Q4 2025, excluding the cash needed for the merger, which is contingent on a new financing round. The combined entity aims to accelerate product innovation and investment by leveraging combined assets and expertise.

Management Comments

• The TuHURA board of directors has unanimously determined that the Mergers are in the best interests of TuHURA; has approved and declared advisable the Merger Agreement, the Mergers and the issuance of shares of TuHURA Common Stock in connection with the Mergers; and recommends that TuHURA stockholders approve the Authorized Share Increase Proposal and Delaware Conversion Proposal.
• The Kineta board of directors has unanimously determined that the Merger Agreement, the Mergers and the other transactions contemplated by the Merger Agreement are fair to and in the best interests of Kineta and its stockholders; has approved and declared advisable the Merger Agreement and the transactions contemplated by the Merger Agreement, including the Mergers and has recommended that Kineta stockholders vote to adopt the Merger Agreement.
• Dr. James Bianco (TuHURA CEO): 'Dr. Bianco was responsible for strategic portfolio development and identifying, acquiring, licensing, purchasing, or acquiring through international merger and acquisition, five drug candidates, four of which have since been approved by the FDA and with three receiving accelerated or conditional regulatory approval in the U.S. and/or E.U.'

Industry Context

The merger occurs within the rapidly evolving immuno-oncology and biopharmaceutical industries, characterized by significant competition and high R&D costs. The global immuno-oncology market is substantial, valued at approximately $111 billion in 2023 and projected to reach $201 billion by 2028. While existing checkpoint inhibitors (CPIs) have revolutionized cancer treatment, they have limitations such as low complete response rates and poor efficacy in many common cancer types. Both TuHURA and Kineta are developing next-generation immunotherapies to address these unmet medical needs by targeting cancer immune resistance mechanisms like immunosuppression and T cell exhaustion. The transaction reflects a trend of strategic consolidation in the biotech sector, where companies combine pipelines and resources to de-risk development and accelerate innovation, particularly in complex areas like tumor microenvironment modulation.

Comparison to Industry Standards

• KVA12123 (Kineta's VISTA blocking immunotherapy) is positioned as differentiated from competitors like Hummingbird Bioscience Pte. Ltd., PharmAbcine, Inc., and Sensei Biotherapeutics, Inc. by its unique epitope binding, binding at physiologic and acidic pH in the TME, strong single-agent tumor growth inhibition, and a well-tolerated profile without cytokine release syndrome (CRS).
• Kineta's anti-CD27 agonist mAb immunotherapy was being developed in a competitive landscape including Merck & Co., Inc. and Celldex Therapeutics, Inc., with Merck having a Phase 2 asset and Celldex having discontinued a bi-specific antibody program.
• TuHURA's IFx-2.0 Phase 3 trial design, developed with the FDA's Oncology Center of Excellence, aims for accelerated approval based on objective response rate (ORR) and progression-free survival (PFS) as a key secondary endpoint, consistent with the FDA's Project Front Runner initiative, which seeks to expedite promising treatments.

Management Changes

Corporate Governance

Legal Proceedings

• Kineta filed a complaint in the Court of Chancery of the State of Delaware against Growth & Value Development Inc. (GVDI) alleging breach of contract for failure to provide substantial funding under a Securities Purchase Agreement.
• Kineta filed a complaint in the Court of Chancery of the State of Delaware against Myron Wolff alleging breach of contract for failure to provide substantial funding under a Securities Purchase Agreement.
• Kineta entered into a settlement agreement and mutual general release with Wolff Family Office LLC to settle the complaint against Myron Wolff, receiving $2,500.

Related Party Transactions

• TuHURA issued Warrant Exercise Promissory Notes totaling $3,011,373 to KP Biotech Group, LLC and CA Patel F&F Investments, LLC, both of whom are holders of more than 5% of TuHURA's capital stock.
• TuHURA had a consulting agreement with an entity owned by Drs. Michael Lawman and Patricia Lawman (former CEO/President and founders of Legacy TuHURA), paying $533,000 annually, which expired on December 31, 2023.
• TuHURA entered into a new consulting agreement with Dr. Patricia Lawman for $500 per hour (not to exceed $25,000 monthly) for clinical strategy and technical consulting.
• TuHURA's CEO, Dr. James Bianco, had a note receivable of $100,000 from TuHURA, which was offset and forgiven against his 2022 cash bonus.
• TuHURA acquired certain assets of TuHURA Biopharma, Inc. for $1.2 million in cash and 4.1 million shares of common stock; Dr. Bianco was the CEO and majority shareholder of TuHURA Biopharma at the time.
• K&V Investment One, LLC, a holder of more than 5% of TuHURA's fully diluted capital stock, participated in TuHURA's Note Financing for $10 million in convertible notes.
• Dr. Kiran Patel, a former director of TuHURA, accepted a six-month extension to the expiration date of his Series A Warrants.
• Kineta issued 903,995 shares of its common stock to a company controlled by a director pursuant to a settlement agreement.
• Kineta issued 5,000 shares of common stock to members of its executive management upon vesting of restricted stock units in 2024.
• Kineta issued 3,000 shares of common stock to executive management and 64,000 shares to a director upon exercise of outstanding warrants in 2023.

Stakeholder Impact

• Kineta Shareholders: Will receive a mix of TuHURA stock and cash, providing a potential exit and participation in the combined entity's future, but with significant dilution and a small ownership stake (approx. 7%). They also receive proceeds from asset sales. However, there's a risk of total loss if the merger fails.
• TuHURA Shareholders: Will experience dilution from the issuance of new shares to Kineta stockholders but gain an expanded pipeline, particularly Kineta's VISTA blocking immunotherapy, which is expected to create synergies and accelerate product innovation.
• Employees (Kineta): Experienced a significant workforce reduction (64%) prior to the merger. Remaining executive officers will receive retention bonuses and severance benefits upon qualifying termination, but overall employee morale and retention could be impacted by the restructuring and uncertainty.
• Employees (TuHURA): Current management team and board are expected to remain, providing continuity. Potential for additional equity awards.
• Customers/Patients: The merger aims to accelerate the development of novel immunotherapies, potentially bringing new treatment options to cancer patients faster, especially for those with unmet medical needs.
• Suppliers/Creditors: Kineta's financial distress and asset sales indicate a challenging environment for its existing suppliers and creditors, though the merger aims to stabilize the combined entity's financial position. The settlement with a landlord and a litigation settlement with an investor indicate efforts to resolve outstanding obligations.

Next Steps

• TuHURA and Kineta stockholders will hold special meetings on June 23, 2025, to vote on the merger and related proposals.
• TuHURA will seek to have its Registration Statement declared effective by the SEC and mail the definitive Proxy Statement/Prospectus to stockholders.
• TuHURA will work to satisfy the FDA's requirements for lifting the partial clinical hold on IFx-2.0's Phase 3 trial, with an expected complete response letter in Q2 2025.
• TuHURA anticipates initiating the IFx-2.0 Phase 3 study in Q2 2025, with enrollment expected to take approximately 12 months.
• TuHURA expects to initiate the Phase 2 arms of the VISTA-101 clinical trial in the second half of 2025.
• TuHURA plans to continue developing its IFx-3.0 mRNA innate immune agonist, with humanized immune competent murine models of aggressive lymphoma planned for 2026.
• TuHURA will continue to develop its novel immune modulating bi-functional ADCs and APCs.
• TuHURA plans to seek and establish partnerships with large pharmaceutical or biotech companies for global development of its product candidates.
• TuHURA will continue to pursue opportunities to secure necessary financing through new equity, debt, and/or strategic partnership arrangements.
• TuHURA's board anticipates the Delaware Conversion to occur following the completion of the Mergers or if the Merger Agreement is terminated.

Key Dates

Recommendation

Keywords

Immuno-oncology, Biotechnology, Merger, Acquisition, SEC Filing, Proxy Statement, Clinical Stage, VISTA Immunotherapy, KVA12123, IFx-2.0, Merkel Cell Carcinoma, Solid Tumors, Asset Sale, Corporate Restructuring, Financial Distress, Nasdaq, OTC Pink Market, Clinical Trials, Regulatory Approval, Biologics, Intellectual Property, Corporate Governance, Capital Raise